#United States #IDEAYA Biosciences #South San Francisco #IDE849 #Hengrui Pharmaceuticals

IDEAYA Biosciences and Hengrui Pharmaceuticals to Present at IASLC 2025

In an exciting development for the oncology community, IDEAYA Biosciences, Inc., a leader in precision medicine focused on cancer treatment, along with Jiangsu Hengrui Pharmaceuticals Co., Ltd., will present significant findings related to IDE849 (SHR-4849) at the IASLC 2025 World Conference on Lung Cancer. This prestigious conference, organized by the International Association for the Study of Lung Cancer, is set to take place from September 6 to 9, 2025, in the vibrant city of Barcelona, Spain.

IDE849 is a prospective first-in-class antibody-drug conjugate (ADC) that targets delta-like ligand 3 (DLL3), a protein often overexpressed in various solid tumors, including small-cell lung cancer (SCLC), neuroendocrine tumors, and other malignancies. The oral presentation will focus on the clinical efficacy and safety data gathered from over 70 patients diagnosed with SCLC, participating in Hengrui's ongoing Phase 1 trial. This multi-site, open-label study is critical in illuminating the potential of IDE849 as a novel treatment option.

The details of the oral presentation are as follows:

• - Title: A first-in-human Phase 1 study of SHR-4849 (IDE849), a DLL3-directed antibody drug conjugate (ADC) in relapsed SCLC.
• - Date and Time: Sunday, September 7, from 4:45 PM to 6:00 PM (CET).
• - Session: OA6 – Novel ADCs in SCLC.

The Phase 1 trial began in the third quarter of 2025, representing an important step forward in the fight against SCLC, which has historically been challenging to treat due to limited effective therapies.

Furthermore, simultaneous to the oral presentation, IDEAYA will showcase a poster that details preclinical data demonstrating the synergistic effects of IDE161, the company’s proprietary PARG inhibitor, in combination with TOP1-payload ADCs like IDE849.

This combination approach appears promising, as it aims to enhance the durability of treatment outcomes for patients suffering from various types of cancer. The proposed poster presentation details are:

• - Control #: 2165
• - Title: Dual PARG-TOP1 Inhibition Exacerbates DNA-Protein Crosslinks and Replication Stress — A Promising Strategy for Enhancing TOP1i-ADC Efficacy.
• - Presenter: Reeja Maskey, Ph.D.
• - Date and Time: Monday, September 8, from 10:30 AM to 12:00 PM (CET).
• - Session: P2.10 - Metastatic Non-small Cell Lung Cancer – Antibody-Drug Conjugate and Cytotoxic Therapy.

IDEAYA's involvement in this conference underscores their commitment to developing innovative cancer therapies designed for specific patient populations, leveraging advanced biomarker discovery and drug development strategies.

Dr. Darrin Beaupre, IDEAYA's Chief Medical Officer, expressed enthusiasm about the Phase 1 trial results, stating, "We are excited to have the first-in-human Phase 1 clinical efficacy and safety data presented by our partner Hengrui for IDE849 in patients with SCLC." Furthermore, Yujiro S. Hata, President and CEO of IDEAYA Biosciences, highlighted the significance of IDE849 and its potential applications in both monotherapy and combination treatments.

The culmination of this collaboration aims to lay the groundwork for further exploration into IDE849 as a viable treatment option in the oncology landscape, where the need for effective therapies remains urgent. As these results are anticipated, the global medical community watches keenly, hoping that this novel ADC will improve the lives of patients battling SCLC and other DLL3-expressing cancers.

For further updates and access to presentations, interested parties are encouraged to follow IDEAYA's website following the conference:
IDEAYA Biosciences Events

With IDEAYA and Hengrui's promising data soon to be unveiled, the IASLC 2025 World Conference is poised to be a significant event for those dedicated to improving cancer treatment options.